Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:CAPR NASDAQ:CRVS NASDAQ:IMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.43+0.9%$5.96$4.07▼$8.40$1.33B0.614.62 million shs3.56 million shsCAPRCapricor Therapeutics$22.25+0.1%$28.13$4.30▼$40.37$1.29B0.421.58 million shs1.46 million shsCRVSCorvus Pharmaceuticals$16.08+2.9%$13.32$3.96▼$26.95$1.31B0.821.28 million shs2.61 million shsIMRXImmuneering$5.53+8.4%$4.86$2.90▼$10.08$329.96M0.411.49 million shs1.59 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.93%+5.23%-1.99%-11.42%+21.21%CAPRCapricor Therapeutics+0.14%-3.55%-14.95%-29.61%+118.78%CRVSCorvus Pharmaceuticals+2.88%+8.94%+44.22%+2.62%+306.06%IMRXImmuneering+8.43%+9.50%+40.71%-2.30%+38.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.43+0.9%$5.96$4.07▼$8.40$1.33B0.614.62 million shs3.56 million shsCAPRCapricor Therapeutics$22.25+0.1%$28.13$4.30▼$40.37$1.29B0.421.58 million shs1.46 million shsCRVSCorvus Pharmaceuticals$16.08+2.9%$13.32$3.96▼$26.95$1.31B0.821.28 million shs2.61 million shsIMRXImmuneering$5.53+8.4%$4.86$2.90▼$10.08$329.96M0.411.49 million shs1.59 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.93%+5.23%-1.99%-11.42%+21.21%CAPRCapricor Therapeutics+0.14%-3.55%-14.95%-29.61%+118.78%CRVSCorvus Pharmaceuticals+2.88%+8.94%+44.22%+2.62%+306.06%IMRXImmuneering+8.43%+9.50%+40.71%-2.30%+38.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.91Moderate Buy$15.73189.64% UpsideCAPRCapricor Therapeutics 2.90Moderate Buy$53.67141.20% UpsideCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33107.30% UpsideIMRXImmuneering 2.86Moderate Buy$16.57199.66% UpsideCurrent Analyst Ratings BreakdownLatest IMRX, ARDX, CRVS, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.006/29/2026ARDXArdelyx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/25/2026CAPRCapricor Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026ARDXArdelyx LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/15/2026CAPRCapricor Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026IMRXImmuneering OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/19/2026IMRXImmuneering Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/15/2026CAPRCapricor Therapeutics Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/13/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M3.29N/AN/A$0.69 per share7.87CAPRCapricor Therapeutics$22.27M57.86N/AN/A$5.53 per share4.02CRVSCorvus PharmaceuticalsN/AN/A$0.13 per share123.31$0.73 per shareN/AIMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A9.70N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)CAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)CRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)IMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)Latest IMRX, ARDX, CRVS, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CRVSCorvus Pharmaceuticals-$0.17N/AN/AN/AN/AN/A8/3/2026Q2 2026ARDXArdelyx-$0.03N/AN/AN/A$126.80 millionN/A5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28CAPRCapricor TherapeuticsN/A8.428.42CRVSCorvus PharmaceuticalsN/A19.8119.81IMRXImmuneeringN/A32.4532.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%CAPRCapricor Therapeutics21.68%CRVSCorvus Pharmaceuticals46.64%IMRXImmuneering67.65%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%CAPRCapricor Therapeutics9.20%CRVSCorvus Pharmaceuticals19.70%IMRXImmuneering22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableIMRXImmuneering6064.70 million49.88 millionNot OptionableIMRX, ARDX, CRVS, and CAPR HeadlinesRecent News About These CompaniesImmuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 1, 2026 | americanbankingnews.comImmuneering (NASDAQ:IMRX) CEO Benjamin Zeskind Purchases 2,400 Shares of StockJune 25, 2026 | insidertrades.comImmuneering Appoints Veteran Biotech Leader as New CFOJune 15, 2026 | tipranks.comImmuneering Appoints Andrew Gengos as Chief Financial OfficerJune 15, 2026 | globenewswire.comIMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock UpJune 12, 2026 | zacks.comImmuneering Shareholders Approve Directors and Auditor at MeetingJune 11, 2026 | tipranks.comImmuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic CancerJune 11, 2026 | quiverquant.comQImmuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic CancerJune 11, 2026 | globenewswire.comIMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?June 2, 2026 | finance.yahoo.comImmuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer TranscriptJune 1, 2026 | seekingalpha.comImmuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with AtebimetinibJune 1, 2026 | quiverquant.comQImmuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCOJune 1, 2026 | globenewswire.comImmuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026May 21, 2026 | quiverquant.comQImmuneering stock jumps on pancreatic cancer trial dataMay 21, 2026 | au.investing.comImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus ChemotherapyMay 21, 2026 | globenewswire.comImmuneering Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 15, 2026 | globenewswire.comWe're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash WiselyMay 6, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)April 23, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Passage Bio (PASG) and Immuneering (IMRX)April 21, 2026 | theglobeandmail.comImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRX, ARDX, CRVS, and CAPR Company DescriptionsArdelyx NASDAQ:ARDX$5.43 +0.05 (+0.93%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$5.46 +0.04 (+0.64%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Capricor Therapeutics NASDAQ:CAPR$22.25 +0.03 (+0.14%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$22.59 +0.34 (+1.53%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Corvus Pharmaceuticals NASDAQ:CRVS$16.08 +0.45 (+2.88%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$16.15 +0.07 (+0.43%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Immuneering NASDAQ:IMRX$5.53 +0.43 (+8.43%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$5.60 +0.06 (+1.18%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
